Udvalget for Humanmedicinske Lægemidler (CHMP) var af den opfattelse, at Reyataz ’ fordele er større end risiciene til behandling af hiv- 1 smittede voksne i kombination med andre antiretrovirale lægemidler.
The Committee for Medicinal Products for Human Use (CHMP) decided that Reyataz’ s benefits are greater than its risks for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products.